{
    "nct_id": "NCT03691207",
    "official_title": "A Phase 2, Open-Label, Multi-center Study of AL101 in Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations",
    "inclusion_criteria": "1. Confirmed Adenoid Cystic Carcinoma with known NOTCH 1/2/3/4 activating mutation that is recurrent or metastatic, not amenable to potentially curative surgery or radiotherapy.\n2. Evidence of radiographic or clinical disease progression within 6-months of signing informed consent; newly diagnosed metastatic patients will be allowed.\n3. Patients must have Formalin-fixed, Paraffin-embedded tissue available .\n4. Must have at least 1 target lesion that is measurable for patients with nodal or visceral metastasis.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Diagnosed with a malignancy other than ACC in the past 2 years.\n2. Uncontrolled, Active Infection\n3. Gastrointestinal (GI) disease with increased risk of diarrhea [e.g. inflammatory bowel disease (IBD)]\n4. Symptomatic central nervous system (CNS) metastases.\n5. Unstable or severe uncontrolled medical condition\n6. Eastern Cooperative Oncology Group (ECOG) performance status â‰¥2.\n7. Abnormal organ and marrow function",
    "miscellaneous_criteria": ""
}